Boston Scientific Q1 sales rise 11.6%, EPS doubles to $0.90, driven by strong cardiovascular and global growth

Boston Scientific reported first-quarter 2026 net sales of $5.203 billion, up 11.6% year-over-year, with adjusted EPS rising to $0.80 from $0.75. Growth was led by cardiovascular and MedSurg segments, with strong sales in the U.S., Asia-Pacific, and Latin America. The company highlighted positive clinical trial results and new product approvals, signaling continued innovation. Full-year 2026 sales growth is forecasted at 7.0-8.5%, with adjusted EPS guidance of $3.34 to $3.41.